Anti-obesity Drugs Market is expanding rapidly with Novo Nordisk announced the Phase IIIa obesity trial for an oral formulation
Weight loss drugs or anti-obesity
drugs are pharmacological substances that regulate weight or reduce it. These
drugs change one of the most fundamental processes of our body, weight
regulation, through altering either absorption appetite or activity of calories
in the body. One of the most obvious reasons for the high adoption of
anti-obesity drugs is rising burden of obesity and relevant chronic diseases.
As per the World Health Organization (WHO), in 2016, over 1.9 billion adults
aged 18 years and above were overweight, of which around 650 million were
obese. As per the same source, in 2016, around 340 million children and
adolescents aged 5-19 years were overweight or obese. Such high incidence of
obesity has necessitated the adoption of effective drugs. Hence, such factors
can stimulate the growth of the anti-obesity drugs market.
Lifestyle and eating habits across
the globe have changed becoming increasingly unhealthy. Such unhealthy cousin
habits are leading to the emergence of many lifestyle-related diseases such as
hypertension, diabetes, obesity, and stress. Thus, such factors could
potentially augment growth of the anti-obesity
drugs market. Recently, in April 2021, Novo Nordisk announced the Phase
IIIa obesity trial for an oral formulation.
The most common and highly prescribed
anti-obesity drug is Aciphexane or AMP. It has been found to be very effective
at suppressing the appetite and keeping one physically alert. Its main
component, chlorogenic acid, stimulates thermogenesis, a process by which the
body produces heat. Research studies have shown that Aciphexane also regulates
nutrient absorption in the intestines, a factor that can also contribute to
obesity. As far as regional impact is concerned, North America seems to be
gaining significant traction in the anti-obesity drugs market. This is
typically due to the high incidence of obesity and overweight cases in the U.S.
On the contrary, Asia Pacific is likely to register promising signs with rising
awareness regarding the risk associated with obesity among the populace.
Most of these drugs have a central
mechanism that involves dopamine, an important neurotransmitter in the brain
and other areas. In fact, dopamine is believed to be responsible for feelings
of pleasure, motivation, and energy. Regardless of how effective these drugs
are, certain issues can be major hurdles in the development of the market.
Since there is the availability of alternative treatment options, the adoption
of the anti-obesity drugs market is likely to be hindered. Besides, side
effects of these drugs can impede growth of the anti-obesity drugs market in
the near future.

Comments
Post a Comment